Price
No data yet.
Social Signal Score
Revenue
$4.02MCompany Profile
- CEO
- David Christensen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Beta
- 1.22
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -24.75
Financials
Revenue
$4.02M+28448.5%Net Income
$-2.91MEBITDA
$656.8KFree Cash Flow
$288.5KEPS (diluted)
$-0.22Shares Outstanding (diluted)
13.22M+646.2%Operating Expenses
$1.87MCash & Debt
$1.32MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.10M | $-7.81M | $-0.62 |
| 2024 | $4.11M | $-5.56M | $-0.44 |
| 2023 | $2.41M | $-9.81M | $-0.79 |
| 2022 | $1.53M | $-5.49M | $-0.45 |
| 2021 | $437.9K | $-12.88M | $-1.12 |
| 2020 | $55.1K | $-5.90M | $-0.63 |
| 2019 | $30.1K | $-2.51M | $-0.47 |
| 2018 | $50.1K | $-2.06M | $-0.50 |
| 2017 | $29.2K | $-377.0K | $-0.11 |
| 2016 | $0.00 | $-4.21M | $-2.34 |
| 2015 | $5.4K | $-1.93M | $-7.82 |
| 2014 | $0.00 | $-4.55M | $-15.60 |
Valuation
RMTGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
110+10.00%Social Signal Score
Mentions (10)
- Newsaccessnewswire.com·1d ago·Positive
RMTG Broadens Longevity Footprint With New ISSCA Certification Across Adjunctive Therapies New ISSCA curriculum covers multiple adjunctive technologies used in longevity-focused practices and is intended to complement clinical capabilities Cellular Hope Institute is developing. MIAMI, FL / ACCESS Newswire / October 5, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem…
View source ↗ - Newsaccessnewswire.com·5d ago·Positive
RMTG Expands Peptide Education Platform With ISSCA Peptide Certification 2.0 and New Physician Reference Guides The upgraded program complements Cellgenic's expanding peptide training product portfolio and is intended as a current example of RMTG's education-to-product operating model. MIAMI, FL / ACCESS Newswire / October 1, 2026 / Oct 1, 2026, Regenerative Medical Technology Group Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned su…
View source ↗ - Newsaccessnewswire.com·19d ago·Neutral
RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) Strategy ISSCA's most comprehensive credential to date integrates regenerative medicine, biotechnology, longevity medicine, and artificial intelligence - a durable, multi-year physician-relationship asset. New multi-component fellowship is designed to combine regenerative medicine, biotechnology, longevity medicine, clinical implementation, and physician-controlled clinical-intellige…
View source ↗ - Newsaccessnewswire.com·22d ago·Neutral
…n - with the physician remaining the decision-maker MIAMI, FL / ACCESS Newswire / September 14, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), operating through its wholly owned subsidiary Global Stem Cells Group, today issued an expanded technology, data, and commercial overview of the ISSCA AI™ Clinical Intelligence Platform. The update describes a more fully specified, physician-facing system for regenerative and longevity medicine: clinics can uplo…
View source ↗ - Newsaccessnewswire.com·35d ago·Neutral
RMTG's Cellgenic Commences Commercial Activity in Peru, Extending Its Latin American Footprint Peru becomes the newest addition to Cellgenic's Latin American commercial network - one of three coordinated market initiatives across the region, subject to applicable local regulatory requirements. MIAMI, FL / ACCESS Newswire / September 1, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subs…
View source ↗ - Newsaccessnewswire.com·40d ago·Neutral
RMTG's Cellgenic Division Introduces MUSE Cell Product Line Across Four International Regions A second cellular-technology launch in close succession broadens Cellgenic's portfolio into Latin America, the Middle East, Europe, and Southeast Asia, demonstrating a repeatable product-development motion. MIAMI, FL / ACCESS Newswire / August 27, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned …
View source ↗ - Newsaccessnewswire.com·41d ago·Negative
RMTG Acquires RMTG.com Domain and Launches New Investor-Focused Website, Advancing Shareholder Engagement New Website Serves as a Central Source for Investor Information and Timely Disclosure; Investor Inquiries Directed to ir@rmtg.com MIAMI, FL / ACCESS Newswire / August 26, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that it has a…
View source ↗ - Newsaccessnewswire.com·43d ago·Neutral
RMTG's Cellgenic Division Launches Natural Killer (NK) Cell Product Line for International Markets New NK cell platform extends RMTG's cellular-technology portfolio into immunology-adjacent applications, with an initial commercial focus on Latin America and Southeast Asia. MIAMI, FL / ACCESS Newswire / August 24, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cell…
View source ↗ - Newsaccessnewswire.com·47d ago·Negative
RMTG More Than Quadruples Revenue and Gross Profit in Q2 2026 Versus Q2 2025, With Operating Income Surpassing $560,000 Continued Acceleration in 2026 With Record Revenue, Expanding Margins, Growth in Operating Profit, and Accelerating Training and Product Supply Sales MIAMI, FL / ACCESS Newswire / August 20, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Gr…
View source ↗ - Newsaccessnewswire.com·47d ago·Neutral
RMTG Provides Details for First-Ever Investor Call to Answer Shareholder Questions Company Announces Date, Time and Connection Details for Its Inaugural Investor Call Following a Strong First Half of 2026 MIAMI, FL / ACCESS Newswire / August 19, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced the connection details for its first-ever in…
View source ↗
Insider trading
Open-market buys and sells by RMTG officers and directors.
No open-market trades in the recent filings. All 6 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
6 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RMTG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.